Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change $ Change
grade D $21.10 2.93% 0.6
ACOR closed up 2.93 percent on Wednesday, January 18, 2017, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: 2017-02-09

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ACOR trend table...

Date Alert Name Type % Chg
Jan 18 NR7 Range Contraction 0.00%
Jan 18 180 Bullish Setup Bullish Swing Setup 0.00%
Jan 12 50 DMA Support Bullish 1.44%
Jan 11 Stochastic Sell Signal Bearish 1.69%
Jan 10 Doji - Bearish? Reversal -1.17%
Jan 6 Stochastic Reached Overbought Other -0.24%
Jan 5 Spinning Top Other 1.69%
Jan 4 Crossed Above 50 DMA Bullish 2.93%
Jan 3 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 8.21%
Dec 30 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 12.23%

Older signals for ACOR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 40.57
52 Week Low 16.4
Average Volume 600,986
200-Day Moving Average 23.75
50-Day Moving Average 20.23
20-Day Moving Average 19.75
10-Day Moving Average 20.96
Average True Range 0.96
ADX 18.01
+DI 20.86
-DI: 18.75
Chandelier Exit (Long, 3 ATRs) 18.77
Chandelier Exit (Short, 3 ATRs) 20.63
Upper Bollinger Band 22.29
Lower Bollinger Band 17.21
Percent B (%b) 0.77
Bandwidth 0.257215